Peek-a-boo: membrane hijacking and the pathogenesis of viral hepatitis.

PubWeight™: 0.92‹?›

🔗 View Article (PMC 3918648)

Published in Trends Microbiol on November 19, 2013

Authors

Zongdi Feng1, Stanley M Lemon2

Author Affiliations

1: Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7292, USA.
2: Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7292, USA; Division of Infectious Diseases, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7292, USA; Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7292, USA. Electronic address: smlemon@med.unc.edu.

Articles cited by this

HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat Med (2001) 8.38

Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet (2010) 7.11

Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology (1991) 6.38

Evolution and taxonomy of positive-strand RNA viruses: implications of comparative analysis of amino acid sequences. Crit Rev Biochem Mol Biol (1993) 6.36

Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med (2007) 5.87

Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science (1973) 5.82

Hepatitis E: an emerging awareness of an old disease. J Hepatol (2008) 4.84

Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med (2007) 4.69

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med (1992) 4.05

A pathogenic picornavirus acquires an envelope by hijacking cellular membranes. Nature (2013) 3.55

Hepatitis E virus. Rev Med Virol (2003) 3.34

Type A viral hepatitis. New developments in an old disease. N Engl J Med (1985) 2.86

Mechanisms for enveloped virus budding: can some viruses do without an ESCRT? Virology (2007) 2.68

Complete nucleotide sequence of an attenuated hepatitis A virus: comparison with wild-type virus. Proc Natl Acad Sci U S A (1987) 2.56

Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor. Proc Natl Acad Sci U S A (2007) 2.38

The ESCRT complexes. Crit Rev Biochem Mol Biol (2010) 2.23

Apical trafficking in epithelial cells: signals, clusters and motors. J Cell Sci (2009) 2.08

Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology (2011) 2.01

Primary isolation and serial passage of hepatitis A virus strains in primate cell cultures. J Clin Microbiol (1984) 1.61

Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol (2008) 1.49

Mutational analysis of glycosylation, membrane translocation, and cell surface expression of the hepatitis E virus ORF2 protein. J Virol (1999) 1.49

Role of microtubules in extracellular release of poliovirus. J Virol (2009) 1.49

Morphogenesis of hepatitis A virus: isolation and characterization of subviral particles. J Virol (1990) 1.44

ORF3 protein of hepatitis E virus is essential for virion release from infected cells. J Gen Virol (2009) 1.41

Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA. Proc Natl Acad Sci U S A (2011) 1.36

Hepatitis E Virus (HEV) strains in serum samples can replicate efficiently in cultured cells despite the coexistence of HEV antibodies: characterization of HEV virions in blood circulation. J Clin Microbiol (2010) 1.28

Pathogenesis of hepatitis A in orally inoculated owl monkeys (Aotus trivirgatus). J Med Virol (1995) 1.28

Disruption of TLR3 signaling due to cleavage of TRIF by the hepatitis A virus protease-polymerase processing intermediate, 3CD. PLoS Pathog (2011) 1.18

Canalicular ABC transporters and liver disease. J Pathol (2012) 1.15

Serum neutralizing antibody response to hepatitis A virus. J Infect Dis (1983) 1.15

Hepatitis A virus capsid protein VP1 has a heterogeneous C terminus. J Virol (1999) 1.15

Monoclonal antibodies raised against the ORF3 protein of hepatitis E virus (HEV) can capture HEV particles in culture supernatant and serum but not those in feces. Arch Virol (2008) 1.10

 Review of the neurological manifestations of hepatitis E infection. Ann Hepatol (2012) 1.08

Proline-rich regions and motifs in trafficking: from ESCRT interaction to viral exploitation. Traffic (2011) 1.08

A PSAP motif in the ORF3 protein of hepatitis E virus is necessary for virion release from infected cells. J Gen Virol (2010) 0.99

Pathogenesis of hepatitis E virus and hepatitis C virus in chimpanzees: similarities and differences. J Virol (2010) 0.99

Tumour susceptibility gene 101 and the vacuolar protein sorting pathway are required for the release of hepatitis E virions. J Gen Virol (2011) 0.93

Production of monoclonal antibodies against hepatitis E virus capsid protein and evaluation of their neutralizing activity in a cell culture system. Arch Virol (2008) 0.92

Non-A, non-B epidemic hepatitis: visualization of virus-like particles in the stool by immune electron microscopy. J Gen Virol (1984) 0.92

Maturation of the hepatitis A virus capsid protein VP1 is not dependent on processing by the 3Cpro proteinase. J Virol (1999) 0.92

Immunoprecipitation and virus neutralization assays demonstrate qualitative differences between protective antibody responses to inactivated hepatitis A vaccine and passive immunization with immune globulin. J Infect Dis (1997) 0.86